Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 2Recurrence 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Ependymoma 1Disease Progression 1Brain Neoplasms 1

Interventions

Lenalidomide 3Bortezomib 3Dexamethasone 2vandetanib 1umbralisib 1ublituximab 1marizomib 1durvalumab 1carotuximab 1avelumab 1Zoledronic Acid 1Vitamin D 1Transplantation, Autologous 1Tamoxifen 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Oxaliplatin 1Melphalan 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Filgrastim 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disease Progression × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡